Lung cancer is the main cause of cancer-related mortality globally. Erlotinib is a tyrosine
kinase inhibitor, affecting both cancerous cell proliferation and survival. The emergence of …

The development of lung cancer treatment has urged the delivery of chemotherapeutics and
diagnostic agents to the lungs and their adjacent lymph nodes. The unavailability of a proper …

Erlotinib-based EGFR targeted therapy has proven significant clinical improvement against
non-small cell lung cancer (NSCLC). However, the anticancer activity of Erlotinib (Ertb) is …

Dendrimers were well-known as a polymeric nanoparticle drug carrier system. Among them,
polyamidoamine (PAMAM) dendrimers were firstly and systematically studied. Herein, to …

Polyamidoamine (PAMAM) dendrimers are extensively researched as potential drug
delivery system thanks to their desirable features such as controlled and stable structures …

Dendrimers are synthetic nano-molecules with spherical structure and a stardust topology.
They have an amphiphilic nature and a hollow structure, with different layers over their …

This study was aimed at developing a nanoparticle strategy to overcome acquired
resistance against erlotinib in non-small cell lung cancer (NSCLC). To load erlotinib on …

Dendrimer, a new class of hyper-branched polymer with predetermined molecular weight
and well-controlled size, has received much attention in nanobiomedical applications such …

Background Polyamidoamine (PAMAM) and polypropylenimine (PPI) dendrimers are the
commercially available and most widely used dendrimers in pharmaceutical sciences and …

We have investigated the effects of combination treatment involving ERL (erlotinib) with a
glycyrrhetinic acid analog, CDODA-Me in overcoming ERL resistance, providing efforts to …